Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

被引：0
|
作者：
Albiges, L. [1 ]
Rini, B. I. [2 ]
Haanen, J. B. A. G. [3 ]
Motzer, R. J. [4 ]
Kollmannsberger, C. K. [5 ]
Negrier, S. [6 ]
Nole, F. [7 ]
Bedke, J. [8 ]
Bilen, M. A. [9 ]
Nathan, P. [10 ,11 ]
Tomita, Y. [12 ]
Huang, B. [13 ]
Ching, K. A. [14 ]
Chudnovsky, A. [15 ]
Robbins, P. B. [16 ]
di Pietro, A. [17 ]
Thomaidou, D. [18 ]
Choueiri, T. K. [19 ,20 ]
机构：
[1] Inst Gustave Roussy, Med Oncol, Villejuif, France
[2] Cleveland Clin, Oncol, Cleveland, OH 44106 USA
[3] Netherlands Canc Inst, Med Oncol, Amsterdam, Netherlands
[4] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[5] British Columbia Canc Agcy, Dept Med Oncol, Vancouver Ctr, Vancouver, BC, Canada
[6] Univ Lyon, Ctr Leon Berard, Med Oncol, Lyon, France
[7] Ist Europeo Oncol, Med Oncol Div Urogenital & Head & Neck Tumours, Milan, Italy
[8] Univ Tubingen, Urol, Tubingen, Germany
[9] Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA
[10] Mt Vernon Canc Ctr, Canc Serv, London, England
[11] East North Herts NHS Trust, London, England
[12] Niigata Univ, Dept Urol, Dept Mol Oncol, Grad Sch Med, Niigata, Japan
[13] Pfizer Inc, Biostat, Groton, CT 06340 USA
[14] Pfizer Inc, Biostat, San Diego, CA USA
[15] Pfizer Inc, Immunooncol, Cambridge, MA USA
[16] Pfizer Inc, Translat Oncol, San Diego, CA USA
[17] Pfizer Inc, Clin Dev, Milan, Italy
[18] Pfizer Hellas, Med Affairs, Athens, Greece
[19] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Dept Genitourinary Oncol, Boston, MA 02115 USA
[20] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
908PD
引用
收藏
页数：2
相关论文
共 50 条
  • [41] First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial
    Vaishampayan, U. N.
    Schoffski, P.
    Ravaud, A.
    Borel, C.
    Song, T.
    Guenther, S.
    Grewal, J.
    Gulley, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of data from a phase III trial
    Sheng, X.
    Bi, F.
    Ren, X.
    Cheng, Y.
    Wang, J.
    Rosbrook, B.
    Jiang, M.
    Guo, J.
    ANNALS OF ONCOLOGY, 2017, 28 : 82 - 82
  • [43] Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Openlabel, Dose-finding and Dose-expansion, Phase 1b Trial
    Gruenwald, Viktor
    Hadaschik, Boris
    EUROPEAN UROLOGY, 2019, 75 (04) : 697 - 698
  • [44] An integrated analysis of radiologic and pathological responses in patients with metastatic renal cell carcinoma who presented with primary renal tumor in situ and received first-line nivolumab plus ipilimumab followed by cytoreductive nephrectomy
    Clemente, Leticia Campos
    Alhalabi, Omar
    Campbell, Matthew T.
    Alonso, Guillermo Corredor
    Hara, Kieko
    Msaouel, Pavlos
    Johns, Andrew C.
    Tang, Chad
    Karam, Jose A.
    Rao, Priya
    Tannir, Nizar M.
    CANCER RESEARCH, 2024, 84 (06)
  • [45] Overall survival analysis from a randomised phase III trial of axitinib vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma
    Hutson, T. E.
    Al-Shukri, S.
    Stus, V. P.
    Lipatov, O. N.
    Shparyk, Y.
    Bair, A. H.
    Rosbrook, B.
    Andrews, G. I.
    Vogelzang, N. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S476 - S477
  • [46] Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
    Choueiri, Toni K.
    Larkin, James
    Oya, Mototsugu
    Thistlethwaite, Fiona
    Martignoni, Marcella
    Nathan, Paul
    Powles, Thomas
    McDermott, David
    Robbins, Paul B.
    Chism, David D.
    Cho, Daniel
    Atkins, Michael B.
    Gordon, Michael S.
    Gupta, Sumati
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Compagnoni, Anna
    Fowst, Camilla
    di Pietro, Alessandra
    Rini, Brian I.
    LANCET ONCOLOGY, 2018, 19 (04): : 451 - 460
  • [47] Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.
    Tannir, Nizar M.
    Motzer, Robert J.
    Plimack, Elizabeth R.
    McDermott, David F.
    Barthelemy, Philippe
    Porta, Camillo
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Kollmannsberger, Christian K.
    Gurney, Howard
    Amin, Asim
    Grimm, Marc-Oliver
    Rini, Brian I.
    Tomita, Yoshihiko
    McHenry, M. Brent
    Mekan, Sabeen Fatima
    Escudier, Bernard
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [48] Nivolumab plus ipilimumab (NIVO plus IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial
    Escudier, Bernard
    Mcdermott, David F.
    Burotto, Mauricio
    Choueiri, Toni K.
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Porta, Camillo
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Atkins, Michael B.
    Kollmannsberger, Christian K.
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Rini, Brian I.
    Jiang, Ruiyun
    Desilva, Heshani
    Lee, Chung-Wei
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 363 - 363
  • [49] Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.
    Burotto, Mauricio
    Powles, Thomas
    Escudier, Bernard
    Apolo, Andrea B.
    Bourlon, Maria Teresa
    Shah, Amishi Yogesh
    Suarez, Cristina
    Porta, Camillo
    Barrios, Carlos H.
    Richardet, Martin
    Gurney, Howard
    Kessler, Elizabeth R.
    Tomita, Yoshihiko
    Bedke, Jens
    George, Saby
    Scheffold, Christian
    Wang, Peter
    Fedorov, Viktor
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [50] PREPARE – Phase-III-Studie zur Erstlinientherapie des unbehandelten fortgeschrittenen oder metastasierten NierenzellkarzinomsProaktive Begleitung der Therapie mit Sunitinib, Pembrolizumab plus Axitinib oder Avelumab plus AxitinibPREPARE—phase III trial of first-line therapy of treatment-naïve advanced or metastatic renal cell carcinomaProactive coaching during treatment with sunitinib, pembrolizumab, and axitinib or avelumab with axitinib
    H. Rexer
    V. Grünwald
    C. Doehn
    Forum, 2021, 36 (3) : 253 - 255
12345